Positive Quality Interventions Help Optimize Drug Therapy and Patient Outcomes

In an effort to promote higher quality patient care the National Community Oncology Dispensing Association, Inc (NCODA), created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance document for healthcare providers.  By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet simple-to-use resource for managing patients receiving oral or IV oncolytics. The PQI fosters better care for patients through appropriate patient identification, treatment selection, increased speed to therapy, reduced cost and hospitalization and by improving adherence techniques for the patient and their medically integrated teams.

The treatment and management of oncology patients on oral drug therapy is continually changing and evolving. The growing complexity creates a need for healthcare professionals to have a quick resource to turn to for drug therapy management information. The medically integrated pharmacy team is in a unique position to ensure appropriate treatment, increase compliance, and maximize outcomes. Positive Quality Interventions (PQIs), an NCODA Quality Standard, are designed to operationalize and standardize those practices to achieve these positive clinical outcomes. We welcome other professionals to join the PQI Committee and contribute relevant topics and potential authors to this growing body of knowledge and, in that way, better serve all patients living with cancer.

SEARCH PQIs

PQI Categories

Abemaciclib: Diarrhea Management

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD

DOWNLOAD HERE

Abemaciclib: Patient Identification

Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy

DOWNLOAD HERE

Afatinib: Non-Small Cell Lung Cancer (NSCLC)

Written by: Chris Sellers, RPh, Texas Oncology

DOWNLOAD HERE

CDK4/6 Inhibitors: Class Overview

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health

DOWNLOAD HERE

Copanlisib: Relapsed Refractory Follicular Lymphoma

Written by: Andrew Kowalski, PharmD, and Osama Abdelghany, PharmD, MHA, BCOP, Smilow Cancer Hospital at Yale New Haven Health 

DOWNLOAD HERE

Duvelisib for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers

DOWNLOAD HERE

Everolimus: Stomatitis Prevention

Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers

DOWNLOAD HERE

Gilteritinib: Acute Myeloid Leukemia

Written by: Bryan J. Brinda, PharmD, Indiana University Simon Cancer Center

DOWNLOAD HERE

Granisetron Transdermal: Chemotherapy-Induced Nausea and Vomiting (CINV)

Written by: Latha Radhakrishnan, PharmD, BCPS, BCOP, University of Illinois Hospital and Health Sciences System

DOWNLOAD HERE

Ibrutinib: Patient Management

Written by: Jody Agena, PharmD, MBA, BCOP

DOWNLOAD HERE

Neratinib Diarrhea Management

Written by: Eric Dallara, RPh, New England Cancer Specialist

DOWNLOAD HERE

Niraparib: Dose Modifications

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center

DOWNLOAD HERE

Olanzapine: Chemotherapy-Induced Nausea and Vomiting (CINV)

Written by: Julianne Orr, PharmD, Indiana University Health Simon Cancer Center

DOWNLOAD HERE

Regorafenib: Hepatocellular Carcinoma (HCC)

Written by: Jody Agena, PharmD, Virginia Cancer Specialists

DOWNLOAD HERE

Regorafenib: Metastatic Colorectal Cancer (mCRC)

Written by: Neal Dave, PharmD, Texas Oncology; Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists 

DOWNLOAD HERE

Ruxolitinib: Myelofibrosis Patient Management

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

DOWNLOAD HERE

Ruxolitinib: Polycythemia Vera Patient Management

Written by: Neal Dave, PharmD, Texas Oncology 

DOWNLOAD HERE

Telotristat Ethyl: Carcinoid Syndrome Diarrhea

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology

DOWNLOAD HERE

Trifluridine and Tipiracil: Gastric Cancer

Written by: Isabel Houlzet, PharmD, BCPS, BCOP Miami Cancer Institute

DOWNLOAD HERE

Trifluridine and Tipiracil: Metastatic Colorectal Cancer (mCRC)

Written by: Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC

DOWNLOAD HERE

Venetoclax: Chronic Lympocytic Leukemia (CLL) Mutation Testing

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

DOWNLOAD HERE

Constipation: Oncolytic-Induced

Written by: Brady Quinn and Britny Rogala, PharmD – University of Rhode Island College of Pharmacy

DOWNLOAD HERE

Constipation: Opioid-Induced

Written by: Neal Dave, PharmD and Julianne Orr, PharmD – NCODA Spring Forum PQI Workshop

DOWNLOAD HERE

Diarrhea: Medication-Induced

Written by: Joshua Nubla, PharmD, NCODA

DOWNLOAD HERE

Hand‐Foot Syndrome: Medication-Induced

Written by: Jonas Congelli, RPh, Hematology Oncology Associates of CNY 

DOWNLOAD HERE

Nausea and Vomiting: Medication-Induced

Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP

DOWNLOAD HERE

Neratinib Diarrhea Management

Written by: Eric Dallara, RPh, New England Cancer Specialist

DOWNLOAD HERE

Peripheral Neuropathy: Medication-Induced

Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP, University of Minnesota Health

DOWNLOAD HERE

Rash: Immunotherapy Treatment-Induced

Written by: Natasha Heimbigner, PharmD, Summit Cancer Centers

DOWNLOAD HERE

Vaccination for Non-Transplant Patients

Written by: Michelle Hoa and Natasha Heimbigner, PharmD, Summit Cancer Centers

DOWNLOAD HERE

Breast Cancer: Abemaciclib

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD

DOWNLOAD HERE

Breast Cancer: CDK4/6 Inhibitors

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health

DOWNLOAD HERE

Carcinoid Syndrome Diarrhea: Telotristat ethyl

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology

DOWNLOAD HERE

Chemotherapy-Induced Nausea and Vomiting (CINV): Granisetron Transdermal

Written by: Latha Radhakrishnan, PharmD, BCPS, BCOP, University of Illinois Hospital and Health Sciences System

DOWNLOAD HERE

Chemotherapy-Induced Nausea and Vomiting (CINV): Olanzapine

Written by: Julianne Orr, PharmD, Indiana University Health Simon Cancer Center

DOWNLOAD HERE

Chronic Lymphocytic Leukemia (CLL): Ibrutinib

Written by: Jody Agena, PharmD, MBA, BCOP

DOWNLOAD HERE

Chronic Lymphocytic Leukemia (CLL): Mutation Testing

Written by: Danny Olszta, PharmD, BCOP, Jolliet Oncology Hematology Associates 

DOWNLOAD HERE

Duvelisib for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers

DOWNLOAD HERE

Gastric Cancer: Trifluridine and Tipiracil

Written by: Isabel Houlzet, PharmD, BCPS, BCOP Miami Cancer Institute

DOWNLOAD HERE

Hepatocellular Carcinoma (HCC): Regorafenib

Written by: Jody Agena, PharmD, Virginia Cancer Specialists

DOWNLOAD HERE

Metastatic Colorectal Cancer (mCRC): Regorafenib

Written by: Neal Dave, PharmD, Texas Oncology; Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists 

DOWNLOAD HERE

Metastatic Colorectal Cancer (mCRC): Trifluridine and Tipiracil

Written by: Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC

DOWNLOAD HERE

Myelofibrosis: Patient Management

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

DOWNLOAD HERE

Non-Small Cell Lung Cancer (NSCLC): Afatinib

Written by: Chris Sellers, RPh, Texas Oncology

DOWNLOAD HERE

Non-Small Cell Lung Cancer (NSCLC): Overview of EGFR Inhibitors

Written by: Danny Olszta, PharmD, BCOP, Jolliet Oncology Hematology Associates

DOWNLOAD HERE

Ovarian Cancer: Niraparib

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center

DOWNLOAD HERE

Polycythemia Vera: Patient Management

Written by: Neal Dave, PharmD, Texas Oncology 

DOWNLOAD HERE

Venetoclax: Risk Stratification, Dosing, and Dispensing Procedure

Written by: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch

DOWNLOAD HERE

PQI Submissions

PQIs are created and written by NCODA members. If you have a relevant topic that highlights a specific aspect of cancer patient care, please contact us for consideration of authorship and incorporation into our library of best practices.

Kirollos Hanna, PharmD, BCPS, BCOP – University of Minnesota Medical Center & Mayo Clinic, MN (Chief Editor)

Neal Dave, PharmD, Chair – Texas Oncology, TX (Chair)

Julianne Orr, PharmD, BCOP, Chair – Indiana University Health, Simon Cancer Center, IN (Chair)

Lawrence Garbo, MD – New York Oncology Hematology, NY (Physician Medical Reviewer)

Wayne Ormsby, MD – Utah Cancer Specialists, UT Hyatt Degreen, MD – Lancaster Cancer Center, PA (Physician Medical Reviewer)

Chara Reid-Reed, PharmD – Dupage Medical Group, IL

Gina Wertz, PharmD – Nebraska Hematology Oncology, NE

Jen Hasiak O’Doherty, PharmD – Hematology & Oncology Consultants Pharmacy

Jody Agena, PharmD, MBA, BCOP – Virginia Cancer Specialists, VA

Lawrence Garbo, MD – New York Oncology Hematology, NY

Lisa Raff, PharmD, BCPS, BCOP – Northwest Oncology & Hematology, IL

Marie Sirek, PharmD – Billings Clinic, MT

Natasha Heimbigner, PharmD – Summit Cancer Centers, WA

Stephanie Matta, PharmD, BCOP – St. Luke’s Health System, ID

Thomas Breedlove, PharmD – Hope Cancer Texas, TX

PQI CORPORATE SPONSORS

NCODA recognizes our PQI corporate sponsors who demonstrate their continued commitment and support to helping NCODA members through this beneficial educational platform.

Important Notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.